4-HO-DET is a lab-made psychedelic that feels a lot like psilocybin but with unique effects. It doesn’t grow in nature but shares a chemical backbone with magic mushrooms. Psychonauts describe 4-HO-DET as clear-headed, colorful, and surprisingly manageable. Researchers see potential for therapy, and low doses could support microdosing. As interest grows, lab testing plays a key role in verifying potency, purity, and safety.
This guide breaks down what 4-HO-DET is, what it does, and why this synthetic compound could play a more significant role in the next wave of psychedelic science.
Researchers classify 4-HO-DET (4-hydroxy-N,N-diethyltryptamine) as a synthetic tryptamine and a close chemical cousin to psilocin. It does not occur naturally in mushrooms or plants. It was first synthesized in the mid-20th century and cataloged in Alexander Shulgin’s TiHKAL.
It is synthetic but semi-natural:
4-HO-DET does not occur in nature. However, researchers discovered that when they introduce DET (a synthetic compound) into the environment of psilocybin-producing mushrooms, the fungi can convert it into 4-HO-DET. This lab-assisted transformation raises interesting questions about what qualifies as “natural”—a nuance brands can explore in messaging or positioning.
Mechanisms
Lab studies confirm that 4-HO-DET activates the 5-HT2A receptor, the primary site associated with psychedelic effects. Compared to psilocin, it has slightly lower potency but still reliably triggers the head-twitch response in animal models—an indicator of hallucinogenic activity.
4-HO-DET also interacts with 5-HT2B and 5-HT2C receptors, which help regulate mood, appetite, and emotional processing. However, high 5-HT2B activation raises potential cardiac safety concerns, especially with frequent use.
4-HO-DET has multiple forms
4-HO-DET exists as a free phenol, acetate ester, and phosphate ester. Each form (like 4-AcO-DET or CEY-19) converts into 4-HO-DET in the body, making 4-HO-DET the active psychedelic molecule. For brands, this matters because 4-HO-DET offers a more direct and predictable experience than its analogs, making it a valuable candidate for product formulation, testing, or research.
4-HO-DET produces a spectrum of effects that vary by dose, setting, and individual sensitivity. People report mild shifts in perception at lower doses (5–10 mg oral). At higher doses (above 20 mg oral), reports range from profound spiritual union to uncomfortable body effects or psychological disorientation. That complexity makes responsible education and lab-tested dosing crucial.
Low Dose (5–10 mg, oral)
Though formal research remains limited, these effects may support microdosing protocols for mood enhancement or cognitive flexibility.
Moderate Dose (10–20 mg, oral)
This range aligns with psycholytic therapy models, where moderate doses facilitate talk therapy without overwhelming intensity.
As one early subject described, “Time really slowed down, with sparkly-ness… there was the compulsion to talk and to interact and to share stuff” (TIHKAL, 4-HO-DET, 15 mg report).
High Dose (20–30+ mg, oral)
In one 30 mg experiment, an Erowid contributor described “complex breathing patterns emerging in walls and textures” and “stars [that] twinkle and glow… producing an aura.” The trip began with disorientation and anxiety but settled into deep conversations, warm body sensations, and a “stimulated feeling.”
**The most common dosage range for 4-HO-DET is 10–25 mg.**
It’s fast-acting and short-lasting:
Consumers report a rapid onset and a 4–6 hour duration, often with fewer lingering aftereffects than LSD. That could appeal to users looking for shorter, manageable trips.
Therapeutic potential:
Psychiatrist Hanscarl Leuner explored 4-HO-DET in over 160 clinical trials and described it as safe and valuable for psycholytic therapy—an approach involving repeated lower-dose psychedelic sessions. That opens up a market conversation about its therapeutic potential in guided, lower-dose experiences.
4-HO-DET occupies a legal gray area in many regions.
United States
In the United States, 4-HO-DET remains unscheduled at the federal level. However, authorities could prosecute possession or sale under the Federal Analogue Act if intended for human consumption.
Finland and Sweden
Several European countries have also banned it. Sweden classifies 4-HO-DET as a health hazard under SFS 2005:733, and Finland prohibits it under its decree on psychoactive substances banned from the consumer market.
What About Safety?
Animal studies on related tryptamines suggest possible cardiotoxicity (heart toxicity or damage), but these results don’t always translate to humans. Because the compound lacks regulation, risks may include inaccurate dosages or unknown impurities. Until more data emerges, responsible use and legal awareness are essential.
Bottom line: 4-HO-DET’s legal status varies, safety data is limited, and risks depend heavily on source and setting. Always test psychedelic compounds and stay informed.
4-HO-DET could be a source for microdosing or therapeutic exploration thanks to its psilocin-like structure and moderate effects. Some psychonauts already use it in varying doses for reasons ranging from mood support to introspective journeying.
Barriers to research include legal ambiguity, limited funding, and Schedule I analog status. However, growing consumer curiosity and a renewed interest in psychedelic wellness could shift the landscape.
Lab testing plays a key role in legitimizing rare tryptamines like 4-HO-DET. Accurate potency data, purity verification, and contaminant screening build trust and reduce risk. As demand for nuanced psychedelic experiences grows, compounds like 4-HO-DET may find a place in the future of safe, informed exploration.
If you’re working with 4-HO-DET or exploring mushroom formulations, connect with ACS Laboratory for potency and purity testing.